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The release of the COURAGE trial results has
fuelled the debate over the benefits of percutaneous
coronary interventions (PCI) in stable angina [1]. To
date PCI, when compared to medical therapy, has
been demonstrated as efficient in this context in
relieving symptoms and improving short-term ex-
ercise performance [2–6]. Although previous ran-
domised studies did not show any reduction in ei-
ther mortality or myocardial infarction rates in the
interventional arms, the trials may have been un-
derpowered to detect such differences, as stents
and evidence-based medical therapies were also un-
derutilised [2–6]. Their limitations have raised con-
siderable concerns as to whether the results ob-
tained are applicable to contemporary clinical prac-
tice. Many cardiologists therefore extrapolated the
evidence for a favourable impact of coronary angi-
oplasty on the hard clinical end points observed in
acute coronary syndromes to the population with
non-acute coronary artery disease.
According to recent data, elective PCI proce-
dures account for approximately 85% and 40% of
all coronary angioplasties in the United States of
America and Poland, respectively [7, 8]. Addition-
ally, increasing numbers of asymptomatic patients
are being referred for PCI with the advent of relia-
ble non-invasive coronary imaging.
The COURAGE study was designed as a strat-
egy trial to compare the long-term outcomes of elec-
tive PCI and provisional revascularisation (i.e. PCI
or coronary artery bypass grafting when angina can-
not be adequately controlled medically or an acute
coronary syndrome occurs) in stable angina sub-
jects. In this multicentre study a total of 2287 pa-
tients, 85% of whom were male and with a mean
age of 61 years, with documented myocardial
ischemia and angiographically confirmed single or
multivessel coronary artery disease were ran-
domised to coronary angioplasty with intensive
medical therapy and lifestyle interventions (n = 1149)
or intensive medical therapy and lifestyle interven-
tions alone (n = 1138). An intention-to-treat anal-
ysis was applied. The study participants were fol-
lowed for a median of 4.6 years. The median time
from the first episode of angina before randomisa-
tion was 5 months. Of these patients 58% had Ca-
nadian Cardiovascular Society class II or III angi-
na, while 38% of participants had suffered a prior
myocardial infarction. Multivessel disease was
present in 69% of patients, with only 31% having
single-vessel disease. Complete revascularisation
was intended in the PCI group. In these patients
59% received one stent and 41% more than one
stent. Drug-eluting stents were implanted in only
31 subjects, as they were not approved until the
final 6 months of the study. Antiplatelet drugs in
the trial comprised aspirin and clopidogrel in the
periprocedural period or clopidogrel indefinitely if
aspirin intolerance was present. Medical anti-
ischemic therapy was based on long-acting meto-
prolol, amlodipine, and isosorbide mononitrate,
alone or in combination. All participants with prior
myocardial infarction were treated with long-acting
metoprolol and those with depressed left ventricu-
lar function (an ejection fraction below 40%) or an-
terior location of the myocardial infarction were also
given lisinopril. Lisinopril was also considered
a first-line antihypertensive treatment, although
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amlodypine, losartan and diuretics might be used.
Moreover, simvastatin alone or in combination with
ezetimibe was started to lower the low-density
lipoprotein (LDL) cholesterol level to a target level
of 60 to 85 mg/dl. After this level was achieved, the
attending physicians made an attempt to raise the
high-density lipoprotein cholesterol levels above
40 mg/dl and reduce triglyceride levels to below
150 mg/dl. If necessary they ordered exercise,
extended-release niacin or fibrate, alone or in combi-
nation. The goal of the antihypertensive therapy
was to achieve and maintain a target blood pressure
of £ 130/85 mm Hg in the general population and
< 130/80 mm Hg in patients with diabetes or chron-
ic renal disease [9]. The goals for diabetes manage-
ment were to maintain fasting blood glucose between
80 and 125 mg/gl and hemoglobin A1c < 7.0%. Smok-
ing cessation along with regular aerobic exercise,
a low-fat diet and weight loss were strongly advised.
Optimal medication use during the study was
high in both treatment groups, with use at 5 years
of angiotensin-converting enzyme inhibitors in 64%
of patients, statins in 93%, aspirin in 95% and beta-
blockers in 85%. LDL levels were reduced to
a median of 71 mg/dl. Blood pressure was also very
well controlled in both study arms. The hemoglob-
in A1c level in diabetic patients fluctuated around
7.0% during the study period. High rates of adher-
ence to diet, regular exercise, and smoking cessa-
tion were demonstrated in both groups. However,
the mean body-mass index did not decrease and
most of the patients remained overweight. In terms
of the primary end point in non-acute patients the
study failed to demonstrate any advantage of elec-
tive PCI over initial intensive medical therapy com-
bined with aggressive modification of risk factors
alone. The composite of death from any cause and
non-fatal myocardial infarction was similar in the
two groups, at 211 in the PCI group and 202 in the
medical therapy only group (the cumulative event
rate was 19.0% and 18.5%, respectively). The se-
condary end point including death from any cause
and non-fatal myocardial infarction and stroke also
occurred at similar frequencies in each group, with
respective rates of 20.0% and 19.5%. Correspond-
ing rates of hospitalisation for acute coronary syn-
drome (12.4% and 11.8%) and myocardial infarction
(13.2% and 12.3%) were also comparable. Although
the degree of angina relief was significantly higher
in the PCI group than in the medical-therapy group
one year and three years after randomisation, the
magnitude of the difference was rather modest (66%
vs. 58% and 72% vs. 67%, respectively). Further-
more, freedom from angina was almost equal in the
two groups at 5 years (74% vs. 72%; p = 0.35).
However, as a result of refractory angina or acute
coronary syndrome, approximately one third of the
patients crossed over from medical therapy to
revascularisation during the study period, a figure
that was higher than anticipated. In a cost-economic
analysis reported by William Weintraub at the
American College of Cardiology 2007 Scientific
Sessions [10] PCI costs averaged $6,020 higher
than medical therapy during the index hospitalisa-
tion (p < 0.0001), a difference that narrowed slightly
over time, but remained at an increased cost of
$5,295 by 3 years (p < 0.0001). In a cost-effective-
ness analysis, PCI was estimated at $217,000 per
quality-adjusted life-year gained, while $50,000 is
often used as the benchmark for acceptable cost-
-effective therapies in the United States of America.
The results of the COURAGE trial are compat-
ible with the current concept of the pathogenesis
of acute coronary syndromes. Tight stenoses, di-
lated during PCI procedures, are markers of the
extent of the process rather than substrates for
acute events. These stable plaques are associated
with constrictive remodelling of the arterial wall
and, as a consequence, they limit the coronary flow
reserve and induce exertional angina. Stable lesions
consist of small lipid cores, few macrophages and
a relatively large number of smooth-muscle cells
and collagen fibres, which are covered by thick
fibrous caps. By contrast, vulnerable plaques, usu-
ally hardly visible on angiography, promote expan-
sive remodelling. These are characterised by high
lipid content, extensive macrophage accumulation,
paucity of smooth muscle cells and collagen. Their
thin fibrous caps are prone to erode or rupture with
superimposed thrombosis, which manifests itself
clinically in acute coronary syndrome or sudden car-
diac death [11]. On the other hand, on the surface
of plaques with severe stenosis, shear stress imposes
a significant risk of thrombosis and sudden occlu-
sion [11]. Nevertheless, non-stenotic lesions are far
more frequent than stenotic plaques and account for
the majority of culprit ruptured plaques [12]. The com-
mon appearance of more than one disrupted plaque
in many patients with an acute coronary syndrome
suggests the systemic nature of the disease [13].
The medical therapy, along with lifestyle interven-
tions, implemented in the COURAGE study were
aimed at diminishing patient vulnerability. Numer-
ous mechanisms were proposed to mediate
a plaque-stabilising effect: anti-inflammatory prop-
erties, reduction of lipid content and thrombotic po-
tential, improvement of endothelial dysfunction, in-
hibition of plaque neovascularisation and a decrease
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in the hemodynamic stress on plaque [14]. Ambro-
se and D’Agate [14] assessed the likelihood that
a given systemic therapy was plaque-stabilising.
They classified statins, angiotensin-converting en-
zyme inhibitors, beta-blockers and aspirin as ther-
apies with biological plausibility and positive clini-
cal evidence. This plaque-stabilising effect exert-
ed by various drugs may be poorly correlated with
angiographic surrogates of atherosclerosis regres-
sion. For example, statins successfully reduce death
and non-fatal myocardial infarction rates with only
a slight decline in the severity of stenosis [15].
It should be emphasised that chronic stable
angina with appropriate medical management pos-
sesses a relatively benign prognosis. Average an-
nual mortality rates range from 1% to 2%, with 1.4%
observed in the optimal medical therapy arm of the
COURAGE study, which is only twice that of age-
matched controls [1, 16, 17]. It is an important con-
sideration when determining the merits of revas-
cularisation treatment [18]. However, an individu-
al’s prognosis may vary considerably. Higher risk
subgroups include patients with poor exercise ca-
pacity and those with easily inducible ischemia or
a poor hemodynamic response to exercise, angina
of recent onset, depressed left ventricular function
and multivessel coronary disease, especially with
involvement of the left main stem or proximal left
anterior descending artery [18]. Current European
guidelines on stable angina recommend referring
for coronary angiography subjects at high risk
(expected annually mortality > 2% per year), while
in the intermediate risk group (expected annually
mortality 1–2% per year) the examination is optional,
depending on the level of symptoms and clinical
judgment [19]. Eugene Braunwald, in a recent in-
terview on the COURAGE results, suggests bas-
ing the risk stratification process on stress per-
fusion imaging and assessment of left ventricle
function. He also supposes that increasingly avail-
able multi-detector computed tomography will be
routinely performed in the immediate future to ex-
clude stenosis of the left main coronary artery [20].
Most of the landmark trials comparing medi-
cal treatment with surgical and percutaneous revas-
cularisation pre-date the widespread use of potent
antiplatelet and cholesterol-lowering drugs, arterial
grafts and coronary stents. Coronary artery bypass
grafting (CABG) is generally recommended for pa-
tients with severe left main stenosis, significant
proximal stenosis of the three major coronary ar-
teries, significant stenoses of two major coronary
arteries, including high-grade stenosis of the prox-
imal left anterior descending artery, and for those
with concomitant valvular heart disease [19]. Addi-
tionally, a meta-analysis conducted by Yusuf et al. [21]
indicated a more pronounced survival gain in sub-
jects with left ventricular dysfunction undergoing
CABG when compared with individuals who had
received medical treatment alone. According to
recently published 10-year clinical outcomes of the
BARI trial, surgery conferred a survival advantage
over balloon angioplasty exclusively among patients
with diabetes mellitus [22]. There is general agree-
ment that CABG gives more sustained relief from
angina, and the need for repeated procedures is
reduced after bypass surgery compared with per-
cutaneous interventions with bare metal stents or
without stents [23, 24]. Evidence in favour of drug-
eluting stents so far is based on short-term follow-
up and mostly on patients with single-vessel dis-
ease [23].
On the other hand, according to current PCI
guidelines, objective evidence of large ischemia is
mandatory to perform coronary angioplasty in sta-
ble angina [25]. It may be considered in almost eve-
ry lesion subset, with the exception of chronic total
occlusions, which cannot be crossed. However, in
non-acute patients with diabetes or multivessel dis-
ease CABG is a preferred method of treatment. PCI
of a left main stenosis in stable patients should only
be performed in the absence of other revasculari-
sation options. PCI can be also recommended in
these subsets when bypass surgery poses a very
high perioperative risk.
In the largest meta-analysis comparing the
long-term outcomes of PCI (n = 1476) and conserv-
ative therapy (n = 1474) in non-acute coronary ar-
tery disease, elective invasive strategy did not offer
any benefit in terms of death, myocardial infarction
or the need for subsequent revascularisation [26].
However, many of the studies included showed
numerous limitations besides a small sample size.
These limitations included low rates of patients who
met the eligibility criteria, the application of balloon
angioplasty, single vessel PCI only, restriction of
a dilated lesion to the particular anatomical locali-
sation, medical therapy left at the discretion of an
attending physician and the utilisation of a single
pharmacological intervention directed against one
risk factor) [2–6]. Moreover, many cardiologists
have questioned whether the conclusions can be
generalised. The results of the meta-analysis per-
formed by Katritsis and Ioannidis [26] are concord-
ant with the COURAGE outcomes and to date in an
overall population of over 5000 patients no effect of
elective PCI on subsequent cardiovascular events
has been demonstrated. Similarly, in a recently
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published Occluded Artery Trial, PCI provided no
benefit in stable patients after myocardial infarction
with persistent occlusion of the infarct-related ar-
tery [27].
The COURAGE trial highlights the benefits of
the initial non-invasive approach, including optimal
pharmacological treatment and implementation of
lifestyle modifications in patients with chronic sta-
ble angina. It provides evidence in support of the
safe deferral of PCI in non-acute patients, and this
can even be avoided in more than two thirds of sub-
jects. In the light of the study, preventive interven-
tions in asymptomatic and mildly symptomatic pa-
tients result in a threat of complications and gen-
erate substantial costs. A considerable change in the
treatment pattern and substantial health care sav-
ings are expected. Subjects with left main disease
or with refractory angina despite optimal medical
therapy, as well as those in a clinically unstable
condition, still remain candidates for revascularisa-
tion [28]. Further trials are warranted to evaluate
the role of CABG in contemporary practice, espe-
cially in the treatment of multivessel disease. The
COURAGE study underscores how effective medi-
cal therapy and risk factor modification are in sec-
ondary prevention as well as angina alleviation, even
in those subjects with extensive multivessel
involvement and inducible ischemia. The COURAGE
findings parallel a tendency recently reported in
the OAT and ICTUS trials, in which observed clin-
ical event rates associated with intensive medical
treatment were lower than expected [27, 29]. More-
over, Mahmarian et al. [30], using intensive medi-
cal therapy, successfully suppressed scintigraphic
ischemia in high-risk but stable survivors of acute
myocardial infarction with preserved left ventricu-
lar function. The effect was as powerful as that de-
rived from revascularisation procedures. On the
other hand, there is considerable doubt concerning
the reproducibility of the COURAGE results in the
real-world setting owing to the high degree of use
of evidence-based medical therapies and the
achievement of the treatment goals by a vast ma-
jority of the study participants. It is noteworthy that
in the Euro Heart Survey of 3779 patients with
a clinical diagnosis of stable angina 78% were treat-
ed with aspirin, 48% with statins, 67% with beta-
-blockers and 37% with angiotensin-converting
enzyme inhibitors [31]. The adherence to guidelines
could be enhanced by close co-operation between
patients and health care providers in the treatment
process.
Patients with depressed left ventricular func-
tion, women and non-white individuals, were under-
represented in the COURAGE trial. Furthermore,
subjects with left main stenosis, very early ST-seg-
ment depression or hypotension on stress testing,
restenosis and coronary artery bypass grafting or
PCI in the preceding 6 months were excluded. The
majority of the PCI group received bare-metal
stents, since most of the enrolment was completed
prior to the introduction of drug-eluting stents.
However, there is no reason to indicate that the use
of drug-eluting stents would alter the findings of the
trial, as, to our knowledge, these stents have nev-
er been shown to reduce the rates of death or myo-
cardial infarction in comparison with bare-metal
stents. The COURAGE results therefore apply to
most, but not all, stable angina patients.
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